Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-40411813 SAD/MAD in Healthy Japanese Men
NCT04677530Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2021
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of adx-71149 in epilepsy and schizophrenia (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Adverse Events up to 8 weeks and Plasma Concentration of JNJ-40411813. Started Jan 2021; status: completed.
02
Drugs
adx-71149
03
Conditions
epilepsyschizophrenia
Beyond the preview
Go deeper on NCT04677530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04677530.